141 related articles for article (PubMed ID: 2465244)
1. Serum antithrombin III and alpha-2-antiplasmin concentration in patients with lung carcinoma.
Dabrowska M; Prokopowicz J; Kemona H; Kretowska J; Kulik S; Głuszczak M
Folia Haematol Int Mag Klin Morphol Blutforsch; 1988; 115(5):641-6. PubMed ID: 2465244
[TBL] [Abstract][Full Text] [Related]
2. [Significance of factors of coagulation and fibrinolysis in progression of lung cancer].
Nagayama M; Tachibana A; Hayakawa H; Sato A
Nihon Kyobu Shikkan Gakkai Zasshi; 1993 Feb; 31(2):180-5. PubMed ID: 8390588
[TBL] [Abstract][Full Text] [Related]
3. [Antithrombin III and alpha 2-antiplasmin in blood of patients operated on for benign prostatic hyperplasia].
Zietek Z; Iwan-Zietek I; Kotschy M; Tyloch F
Pol Tyg Lek; 1996 Feb; 51(6-9):75-6. PubMed ID: 8756735
[TBL] [Abstract][Full Text] [Related]
4. [Plasma levels of antithrombin III, thrombin-antithrombin III complex, alpha 2 plasmin inhibitor and plasmin alpha 2 plasmin inhibitor complex in normal and sick newborn infants].
Shiiki M; Ariyoshi N; Nakamura T; Shirahata A
Rinsho Ketsueki; 1991 Jul; 32(7):758-65. PubMed ID: 1833569
[TBL] [Abstract][Full Text] [Related]
5. Evaluation of platelet activation, plasma antithrombin III and alpha2-antiplasmin activities in hypertensive patients.
Tomczykowska M; Bielak J; Bodys A
Ann Univ Mariae Curie Sklodowska Med; 2003; 58(1):15-20. PubMed ID: 15314952
[TBL] [Abstract][Full Text] [Related]
6. Clinical significance of the ratio between the alpha 2 plasmin inhibitor-plasmin complex and the thrombin-antithrombin complex in advanced non-small cell lung cancer.
Masago K; Fujita S; Mio T; Togashi Y; Kim YH; Hatachi Y; Fukuhara A; Irisa K; Sakamori Y; Mishima M
Med Oncol; 2011 Mar; 28(1):351-6. PubMed ID: 20300980
[TBL] [Abstract][Full Text] [Related]
7. Thrombin-antithrombin complex and alpha-plasmin inhibitor-plasmin complex levels in singleton and twin pregnancies.
Hayashi M; Fukasawa I; Inaba N
Int J Clin Pract; 2006 Oct; 60(10):1244-9. PubMed ID: 16669831
[TBL] [Abstract][Full Text] [Related]
8. Activation of coagulation and fibrinolysis following OKT3 administration to renal transplant recipients: association with distinct mediators.
Raasveld MH; Hack CE; ten Berge IJ
Thromb Haemost; 1992 Sep; 68(3):264-7. PubMed ID: 1279831
[TBL] [Abstract][Full Text] [Related]
9. [Studies on coagulation-fibrinolytic system in diabetic nephropathy--with reference to plasma TAT and alpha 2PIC].
Watanabe S; Ogihara T; Iyori S; Kaneshige H; Nomoto Y; Sakai H
Nihon Jinzo Gakkai Shi; 1990 Sep; 32(9):995-9. PubMed ID: 2148199
[TBL] [Abstract][Full Text] [Related]
10. Antithrombin III, plasminogen, plasmin, and alpha-2-antiplasmin in donor blood and plasma components.
McRoyan DK; McRoyan CJ; Sauter KL; Liu PI; Daniel SJ
Ann Clin Lab Sci; 1985; 15(2):165-70. PubMed ID: 3158265
[TBL] [Abstract][Full Text] [Related]
11. Assessment of the relative contribution of different protease inhibitors to the inhibition of plasmin in vivo.
Levi M; Roem D; Kamp AM; de Boer JP; Hack CE; ten Cate JW
Thromb Haemost; 1993 Feb; 69(2):141-6. PubMed ID: 7681223
[TBL] [Abstract][Full Text] [Related]
12. Correlation between increased granulocyte elastase release and activation of blood coagulation in patients with lung cancer.
Gabazza E; Taguchi O; Yamakami T; Machishi M; Ibata H; Suzuki S
Cancer; 1993 Oct; 72(7):2134-40. PubMed ID: 7690680
[TBL] [Abstract][Full Text] [Related]
13. [Clinical relevance of determination of plasma ATIII and alpha 2 PI activities in patients with DIC--application of the molecular markers for the analysis of pathophysiology of DIC].
Okajima K
Rinsho Byori; 1994 Jan; 42(1):45-55. PubMed ID: 8107283
[TBL] [Abstract][Full Text] [Related]
14. High plasma level of plasmin-alpha 2-plasmin inhibitor complex is predictor of poor prognosis in patients with lung cancer.
Taguchi O; Gabazza EC; Yoshida M; Yamakami T; Kobayashi H; Shima T
Clin Chim Acta; 1996 Jan; 244(1):69-81. PubMed ID: 8919202
[TBL] [Abstract][Full Text] [Related]
15. Serum antithrombin III and alpha-2-antiplasmin concentrations in patients with Hodgkin's disease in the course of chemotherapy.
Dabrowska M; Kemona H; Prokopowicz J; Kretowska J; Kiluk S
Neoplasma; 1991; 38(3):249-52. PubMed ID: 1713303
[TBL] [Abstract][Full Text] [Related]
16. [Changes in protein C inhibitor in disseminated intravascular coagulation: relationship with heparin cofactor II and alpha 2-plasmin inhibitor].
Kazama Y; Takahashi K; Oguma Y; Sakuragawa N
Rinsho Ketsueki; 1988 Mar; 29(3):344-8. PubMed ID: 3398266
[No Abstract] [Full Text] [Related]
17. Increased circulating levels of thrombin-activatable fibrinolysis inhibitor in lung cancer patients.
Hataji O; Taguchi O; Gabazza EC; Yuda H; D'Alessandro-Gabazza CN; Fujimoto H; Nishii Y; Hayashi T; Suzuki K; Adachi Y
Am J Hematol; 2004 Jul; 76(3):214-9. PubMed ID: 15224354
[TBL] [Abstract][Full Text] [Related]
18. Effects of direct percutaneous transluminal coronary angioplasty treatment of acute myocardial infarction on plasma levels of haemostatic and fibrinolytic factors.
Saito M; Nakabayashi T; Iuchi K; Ishikawa T; Kaseno K; Yoshida T; Asakura H; Matsuda T
Blood Coagul Fibrinolysis; 1993 Oct; 4(5):801-4. PubMed ID: 7507363
[TBL] [Abstract][Full Text] [Related]
19. Correlation between clotting and collagen metabolism markers in rheumatoid arthritis.
Gabazza EC; Osamu T; Yamakami T; Ibata H; Sato T; Sato Y; Shima T
Thromb Haemost; 1994 Feb; 71(2):199-202. PubMed ID: 7514817
[TBL] [Abstract][Full Text] [Related]
20. Coagulation and fibrinolysis activation markers in prostatic carcinoma patients.
Geenen RW; Delaere KP; van Wersch JW
Eur J Clin Chem Clin Biochem; 1997 Feb; 35(2):69-72. PubMed ID: 9056745
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
